Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Frequently asked questions
What sector does Aura Biosciences Inc (AURA) operate in?
Aura Biosciences Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Aura Biosciences Inc (AURA) current stock price?
As of the latest data, Aura Biosciences Inc stock price is $7.68, with a previous close of $7.69. Aura Biosciences Inc lost -$0.01 in the last trading session, representing a -0.13% loss.
What is Aura Biosciences Inc (AURA) current market capitalization?
Aura Biosciences Inc market cap is approximately 794.39 million.
What is Aura Biosciences Inc (AURA) Earnings Per Share (EPS)?
The trailing EPS is -$1.73, and the forward EPS is -$1.52.
What is Aura Biosciences Inc (AURA) EBITDA?
Aura Biosciences Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -48.07 million.
Does Aura Biosciences Inc (AURA) pay dividends?
No. Aura Biosciences Inc does not pay a dividend.
What is Aura Biosciences Inc (AURA) beta (volatility) score?
Aura Biosciences Inc has a beta of 0.396, indicating lower volatility than the overall market.
